Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technetium Pyrophosphate Blood Pool Uptake Mistaken for Myocardial Uptake in Light-Chain Amyloidosis: A Dangerous Misinterpretation.

JACC. Case reports·2026
Same author

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with <sup>124</sup>I-evuzamitide (<sup>124</sup>I-p5+14, AT-01).

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026
Same author

Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging.

European heart journal. Cardiovascular Imaging·2025
Same author

Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.

JACC. Cardiovascular imaging·2025
Same author

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.

Blood·2025
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
Same journal

Lessons from ATTR-CM clinical trials: Progress, persistent disparities, and emerging treatment dilemmas.

Progress in cardiovascular diseases·2026
Same journal

Circulating microRNA signatures associated with atrial remodeling in endurance athletes with PAFIYAMA syndrome: A case-control study.

Progress in cardiovascular diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

Amyloid heart disease.

Rodney H Falk1, Simon W Dubrey

  • 1Harvard Vanguard Medical Associates, Harvard Medical School, Boston, MA 02215, USA. rfalk@partners.org

Progress in Cardiovascular Diseases
|January 30, 2010
PubMed
Summary
This summary is machine-generated.

Systemic amyloidoses involve amyloid deposition in organs, often affecting the heart and causing cardiomyopathy. Accurate diagnosis and biochemical typing are crucial for effective treatment and improved prognosis.

More Related Videos

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Related Experiment Videos

Last Updated: Jun 16, 2026

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Area of Science:

  • Cardiology
  • Hematology
  • Pathology

Background:

  • Systemic amyloidoses are rare disorders with amyloid deposition in organs.
  • Cardiac involvement is frequent, manifesting as infiltrative/restrictive cardiomyopathy.
  • Cardiac amyloidosis can be the initial presentation or found during non-cardiac investigations.

Purpose of the Study:

  • To review the diverse features and manifestations of cardiac amyloidosis.
  • To emphasize the importance of early suspicion and accurate diagnosis.
  • To highlight the impact of recent therapeutic advancements.

Main Methods:

  • Review of clinical features and diagnostic approaches for cardiac amyloidosis.
  • Discussion of biochemical typing of amyloid deposits.
  • Analysis of treatment strategies and prognostic implications.

Main Results:

  • Cardiac amyloidosis presents with varied clinical manifestations.
  • Accurate biochemical typing of amyloid is essential for targeted therapy.
  • Timely and appropriate treatment significantly improves patient outcomes.

Conclusions:

  • Cardiac amyloidosis requires a high index of suspicion for timely diagnosis.
  • Precise biochemical typing guides therapeutic decisions.
  • Advances in therapy offer improved prognosis for systemic amyloidoses with cardiac involvement.